EANS-News: MIV Therapeutics Inc. / MIV THERAPEUTICS UPDATE ON CONTRACTS

--------------------------------------------------------------------------------
Corporate news transmitted by euro adhoc. The issuer/originator is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------

Contracts

Richmond BC (euro adhoc) - April 30, 2012, Vancouver, British
Columbia (OTC Pinks: MIVI) MIV Therapeutics, Inc. (the "Company" or
"MIV") announced that MIV finalize the arrangement of payment with
Purple Medical Solution of India for the sale of MIV India division,
in which accordingly to the fifth amended Sale and Purchase Agreement
between the two parties, Purple Medial Solution will settle the
outstanding balance by monthly payment before Oct 2012, with
immediate effect. Furthermore,the two parties will continue to
endeavor to a new structure in order to inject an operating stent
manufacturer with significant revenue and profit as major shareholder
of current MIV Therapeutics, and MIV will develop further market
expansion as well as CE marking accreditation for the best interest
of all shareholders. MIV has also engaged one of the leading IR
companies Euro Ad Hoc as its agent in Europe to facilitate the
investors relationship as part of MIV's further marketing and
branding process as part of the strategic plan.

About MIV Therapeutics, Inc.

MIV Therapeutics, Inc. is a development stage company in the business
of developing next-generation coatings and drug-delivery systems for
cardiovascular stents and other implantable medical devices.

Safe Harbour Statements

Except for the statements of historical fact contained herein, the
information presented in this news release constitutes
"forward-looking statements" as such term is used in applicable
United States and Canadian laws. These statements relate to analyses
and other information that are based on forecasts of future results,
estimates of amounts not yet determinable and assumptions of
management. Any statements that express or involve discussions with
respect to predictions, expectations, beliefs, plans, projections,
objectives, assumptions or future events or performance (often, but
not always, using words or phrases such as "expects" or "does not
expect", "is expected", "anticipates" or "does not anticipate",
"plans, "estimates" or "intends", or stating that certain actions,
events or results "may", "could", "would", "might" or "will" be
taken, occur or be achieved) are not statements of historical fact
and should be viewed as "forward-looking statements". Such forward
looking statements involve known and unknown risks, uncertainties and
other factors which may cause the actual results, performance or
achievements of the Company to be materially different from any
future results, performance or achievements expressed or implied by
such forward-looking statements.

Forward looking statements are made based on management's beliefs,
estimates and opinions on the date the statements are made and the
Company undertakes no obligation to update forward-looking statements
if these beliefs, estimates and opinions or other circumstances
should change, except as required by applicable law. Although the
Company believes that the beliefs, plans, expectations and intentions
contained in this news release are reasonable, there can be no
assurance those beliefs, plans, expectations or intentions will prove
to be accurate. Such forward-looking statements reflect our current
views with respect to future events and are subject to certain risks,
uncertainties and assumptions, including, the risks and uncertainties
outlined in our most recent financial statements and reports filed
with the United States Securities and Exchange Commission (the "SEC")
(available at www.sec.gov) and with Canadian securities
administrators (available at www.sedar.com). Investors should
consider all of the information set forth herein and should also
refer to the risk factors disclosed in the Company's periodic reports
filed from time-to-time with the SEC. The Company again cautions
investors that the Company is not up-to-date in its SEC or SEDAR
filings. Pink OTC Markets has discontinued the display of quotes on
otcmarkets.com for the Company's securities because the Company's
securities have been labeled Caveat Emptor (Buyer Beware) and because
adequate current information has not been made available by the
Company.

This news release shall not constitute an offer to sell or the
solicitation of an offer to buy securities of the Company nor shall
there be any sale of these securities in any jurisdiction in which
such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
jurisdiction.

Contacts:
MIV Therapeutics, Inc.
Fax: +1 604 357 1640

Further inquiry note:
Fax: +1 604 357 1640

end of announcement euro adhoc
--------------------------------------------------------------------------------

company: MIV Therapeutics Inc.
Viking Way #250-4320
CA-V6V2L4 Richmond BC
FAX: +1 604 357 1640
sector: Pharmaceuticals
ISIN: US55306V2051
indexes:
stockmarkets: free trade: Stuttgart
language: English